GRAIL to Announce Third Quarter 2026 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for GRAL
Across the 29 sessions after earlier GRAL headlines, the stock closed higher 15 times and lower 14 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GRAL | SPY |
|---|---|---|---|
| Oct 6, 2026 | GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 | -10.9% | +0.5% |
| Sep 24, 2026 | FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test | +15.4% | -0.1% |
| Sep 17, 2026 | RBC Capital Mkts initiated coverage on GRAIL with a new price target | +6.4% | +1.1% |
| Sep 9, 2026 | UBS resumed coverage on GRAIL with a new price target | -2.0% | -0.5% |
| Sep 4, 2026 | GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | -0.3% | -0.4% |
| Sep 1, 2026 | GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference | +0.5% | -0.7% |
Quantisnow market dataNASDAQ
GRAL
GRAIL Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
Get push alerts for GRAL
Full GRAL profile on Quantisnow Follow GRAL and get a push notification the moment its next story breaks.